Challenging Diagnosis of a Solitary Retroperitoneal Mass: A Case Report of Castleman’s Disease and Review of the Literature

Carrión, Diego M; Álvarez‐Maestro, Mario; Rivas, Juan Gómez; Brygadyr, Yaroslav; García-Fernández, Eugenia; Martínez‐Piñeiro, Luis

doi:10.1159/000493511

Cited by 5 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Overall, our ndings are largely consistent with prior reviews on this topic. Speci cally, six recent reviews examined 1 or more of our 3 outcomes of interest (52)(53)(54)(55)(56)(57). Two systematic reviews examined only the Decipher test (55,57).…”

Section: Discussionmentioning

confidence: 99%

“…As with our ndings, each review noted that genomic classi er tests modestly improve clinical outcome prediction compared to clinical features alone. A few earlier reviews summarized the results of this rapidly changing eld but did not employ standard systematic review methodology such as including a formal risk of bias assessment (52,58). Our review adds to prior reviews by adding a signi cant number of studies, more recent studies (an additional 12 articles since the last review's search period), formal risk of bias and certainty of evidence assessment for all included studies, and exploration of test effects by key subgroups.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Genomic classifiers and prognosis of localized prostate cancer: a systematic review

Boyer,

Carpenter,

Gingrich

et al. 2024

Prostate Cancer Prostatic Dis

View full text Add to dashboard Cite

BackgroundRe nement of the risk classi cation for localized prostate cancer is warranted to aid in clinical decision making. A systematic analysis was undertaken to evaluate the prognostic ability of three genomic classi ers, Decipher, GPS, and Prolaris, for biochemical recurrence, development of metastases and prostate cancer speci c mortality in patients with localized prostate cancer. MethodsData Sources: MEDLINE, Embase, and Web of Science were queried for reports published January 2010 to April 2022.Study Selection: Prospective or retrospective studies reporting prognosis for patients with localized prostate cancer.Data Extraction: Relevant data were extracted into a customized database by 1 researcher with a second over reading. Risk of bias was assessed using a validated tool for prognostic studies, Quality in Prognosis Studies (QUIPS). Disagreements were resolved by consensus or by input from a third reviewer.We assessed certainty of evidence by GRADE incorporating adaptation for prognostic studies. ResultsData Synthesis: A total of 39 studies (37 retrospective) involving over 10 000 patients were identi ed. Twenty-two assessed Decipher, 5 GPS, and 14 Prolaris. Thirty-four studies included patients who underwent prostatectomy. Based on very low to low certainty of evidence, each of three genomic classi ers modestly improved upon the prognostic ability for biochemical recurrence, development of metastases, and prostate cancer speci c mortality compared to standard clinical risk classi cation schemes Limitations: Downgrading of con dence in the evidence stemmed largely from bias due to the retrospective nature of the studies, heterogeneity in treatment received, and era in which patients were treated (i.e., prior to 2000s). Conclusions:Genomic classi ers provide a small but consistent improvement upon the prognostic ability of clinical classi cation schemes which may be helpful when treatment decisions are uncertain. However, de nitive evidence from current management-era data is needed.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Genomic classifiers and prognosis of localized prostate cancer: a systematic review

Boyer,

Carpenter,

Gingrich

et al. 2024

Prostate Cancer Prostatic Dis

View full text Add to dashboard Cite

show abstract

“…When CD is located in the suprarenal region it is easily mistaken for a suprarenal gland tumour, such as pheochromocytoma. In light of the risk of adverse events during procedures in patients with pheochromocytoma, it is important to consider this entity in the differential diagnosis of a suprarenal mass [2] , and wait for all necessary laboratory results to exclude this diagnosis before initiating any procedures. Unicentric CD (UCD) involves one lymph node or a ganglion region, and in the majority of patients (60%) systemic symptoms are absent.…”

Section: Discussionmentioning

confidence: 99%

Unicentric Castleman Disease and Pheochromocytoma

Maia

Couto

Martins

et al. 2022

European Journal of Case Reports in Internal Medicine

View full text Add to dashboard Cite

Castleman disease is an uncommon and heterogenous lymphoproliferative disorder which is classified as unicentric or multicentric depending on the number of lymph nodes involved. Each type has a different clinical presentation, aetiology, treatment and prognosis. We report the case of a young woman who presented with cervical lymphadenopathy and a retroperitoneal mass, and was diagnosed with unicentric Castleman disease and pheochromocytoma. We describe the diagnostic steps, the complications that developed, and the importance of the differential diagnosis in the evaluation of these patients.

show abstract

“…The final diagnosis is only made after histopathology. Retroperitoneum is a rare localization, where initial imaging diagnosis is unclear and surgical resection is the preferred treatment [8] .…”

Section: Introductionmentioning

confidence: 99%

Retroperitoneal unicentric Castleman's disease—A case report and review of literature

Singh

Prasher

Mohan

et al. 2021

International Journal of Surgery Case Reports

View full text Add to dashboard Cite

Introduction and importance Castleman's disease is not so commonly diagnosed worldwide due to non-specific symptoms Clinical findings are variable. No definite blood investigation or any biomarkers are established to diagnose this disease. Radiological investigations do not play much role in diagnosing. It can be unicentric or multicentric. Etiological factors are not well understood except predilection of this disease towards immune-compromised persons. Surgery is considered as a prime modality to treat, if resectable. Case presentation Patient had recurrent abdominal pain in left lumbar region which was intermittent for last 6 months, dull aching with no aggravating and relieving factors. There was no history of abnormal bowel habits, urinary complaints, fever, night sweats, weight loss, rashes in body, joint pains and loss of appetite. On examination, there was a single, firm, non-tender, intra-abdominal, retroperitoneal mass of approximately size 10 ∗ 7 cm in left lumbar region encroaching inferiorly towards left inguinal region. Digital rectal examination (DRE) and external genitalia were normal. Clinical discussion All routine blood investigations along with relevant tumour markers were normal. Magnetic Resonance Imaging (MRI) abdomen showed a well-defined mass suggestive of stromal tumour or retroperitoneal sarcoma. Patient underwent surgery in which complete excision of the mass was done. Postoperative event was uneventful and currently doing well. Conclusion Take away lesson in this case report is that we should not presume all retroperitoneal mass as cancer or sarcoma, we have to think about other rare causes like Castleman's disease, if clinical picture, blood and radiological investigation are discordant.

show abstract

Challenging Diagnosis of a Solitary Retroperitoneal Mass: A Case Report of Castleman’s Disease and Review of the Literature

Cited by 5 publications

References 0 publications

Genomic classifiers and prognosis of localized prostate cancer: a systematic review

Genomic classifiers and prognosis of localized prostate cancer: a systematic review

Unicentric Castleman Disease and Pheochromocytoma

Retroperitoneal unicentric Castleman's disease—A case report and review of literature

Contact Info

Product

Resources

About